wingtrade
6 년 전
Vanc Pharma hires Transcend for IR services
2018-08-23 16:42 ET - News Release
Mr. Bob Rai reports
Vanc Pharmaceuticals Inc. has entered into a consulting agreement with Transcend Capital Inc. to develop and implement an investor relations program for the company. Transcend, with offices in Vancouver, B.C., is a full-service investor relations firm that assists small and mid-cap public companies with market awareness campaigns, and helps these companies gain valued industry exposure through an extensive network of retail and institutional clients. Etienne Moshevich is the sole owner of Transcend.
Transcend will provide comprehensive investor relations services to the company for an initial period of 24 months for an aggregate fee of $150,000 plus applicable taxes. Transcend and its directors, officers and employees are shareholders of the company, collectively holding approximately 3.5 per cent of the issued and outstanding common shares of the company.
The investor relations consulting agreement is subject to the approval of the TSX Venture Exchange.
About Vanc Pharmaceuticals Inc.
Vanc Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, Vanc is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aVANC-2650215&symbol=VANC®ion=C
wingtrade
6 년 전
Emerald Health Therapeutics Inc.
Exchange: TSXV Exchange
$4.65 Aug 23, 2018, 4:00 PM EDT 0.35 (8.14%)Vol: 5,348,395
Boom another huge day for big bad EMH... Quiet little TSX VANC waiting for the signal from big bro EMH, tick tock NUVPF, hopefully soon we have timely and significant updates. Gltua here with VANC/NUVPF and EMH/EMHTF.
wingtrade
6 년 전
Vanc Pharmaceuticals 5,327,335-share private placement
2018-07-31 16:47 ET - Private Placement
The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced July 11, 2018.
Number of shares: 5,327,335 shares
Purchase price: 15 cents per share
Warrants: 5,327,335 share purchase warrants to purchase 5,327,335 shares
Warrant initial exercise price: 33 cents
Warrant term to expiry: two years
Number of placees: 16 placees
Finders' fees: PI Financial Corp., $4,320 cash and 28,800 warrants; First Republic Capital Corp., $9,000 cash and 60,000 warrants
Finder's warrant initial exercise price: 33 cents
Finder's warrant term to expiry: may purchase one common share for up to two years from closing at 33 cents per common share
Note that in certain circumstances the exchange may later extend the expiry date of the warrants if they are less than the maximum permitted term.
July 30, 2018
Item 3 News Release
The news release was disseminated on July 30, 2018 by way of the facilities of Stockwatch. Copies were also filed on SEDAR with the British Columbia Securities Commission and the Alberta Securities Commission.
Item 4 Summary of Material Change
Item 5 Full Description of Material Change
5.1 Full Description of Material Change
The Company announced that further to its news release dated July 11, 2018, it has closed a non-brokered private placement of 5,327,335 units (“Units”) of the Company at a price of $0.15 per Unit for gross proceeds of approximately CDN$799,100 (the “Offering”).
Each Unit consists of one (1) common share of the Company (a “Common Share”) and one (1) share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share for a period of two (2) years following the closing date at a price of $0.33 per Common Share.
The securities issued pursuant to the Offering are subject to a four (4) month hold period, which will expire on December 1st, 2018.
The Company paid aggregate finder’s fees of CDN$13,320 (6% on $222,000) and issued 88,800 finder’s warrants (6% on 1,480,000 Units). Each finder’s warrant entitles the finder to purchase one (1) Common Share for a period of two (2) years following the closing date at a price of $0.33 per Common Share.
Proceeds from the Offering are planned to be used by VANC for corporate overhead and working capital.
Completion of the Offering is subject to all required regulatory approvals, including final acceptance by the TSX Venture Exchange.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aVANC-2640065&symbol=VANC®ion=C